fbpx

Weekly Top News – Psoriasis – February 10, 2020

February 10, 2020

Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
Brodalumab: Regulatory decision in Asia for psoriasis in 2020 (Kyowa Hakko Kirin Pharma) – Feb 6, 2020 – FY 2019 Results
Non-US regulatory
[Screenshot]

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi: Data from P3 trial (NCT03478787) for psoriasis in 2020 (AbbVie) – Feb 8, 2020 – Pipeline Update 
[Screenshot]

 

mirikizumab (LY3074828) / Eli Lilly
OASIS-1: A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) – Feb 5, 2020 – P3; N=530; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting –> Completed

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
AbbVie reports full-year and fourth-quarter 2019 financial results (PRNewswire) – Feb 7, 2020 – “‘The launches of Skyrizi and Rinvoq are going extremely well, and we are entering 2020 with substantial momentum. We also look forward to completing the planned Allergan acquisition in the first quarter.’…Global SKYRIZI net revenues were $216 million and global RINVOQ net revenues were $33 million….Detailed data from both pivotal studies will be presented at an upcoming medical meeting and AbbVie expects to submit our regulatory applications for RINVOQ in PsA in the second quarter of this year.”

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Expiry of patents on method of use for psoriasis in US in 2032 and EU/Japan in 2031 with patent term extension in Japan in 2032-2033 (Novartis) – Feb 2, 2020 – Annual Report 2019: Expiry of patent on method of use for AS in US in 2033 and psoriatic arthritis in Japan in 2031; Pediatric exclusivity in EU until 2030

 

PF-06763809 / Pfizer
Termination of Karo agreement with Pfizer (PRNewswire.co.uk) – Feb 4, 2020 – “Karo Pharma AB…has been informed by Pfizer Inc….about its decision to terminate the Research Collaboration and License Agreement, which the two companies entered in December 2011. Following the wind-down of this agreement, there will be no active collaboration agreements between the two companies. This information follows Pfizer’s decision to terminate a specific development project, PF-06763809, which Karo informed about in press releases issued on November 5th and November 20th, 2019.”

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Efficacy and Safety Study of SUNPG1623 (clinicaltrials.gov) – Feb 6, 2020 – P2b; N=391; Completed; Sponsor: Sun Pharma Global FZE; Active, not recruiting –> Completed

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Expiry of composition-of-matter patent in EU/Japan in 2025 and US in 2026 with patent term extensions in US until 2029 and Japan between 2026-2028-2029 (Novartis) – Feb 2, 2020 – Annual Report 2019: Regulatory data protection in US until 2027, EU until 2026 and Japan until 2022; SPC in EU until 2030

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
AbbVie’s Skyrizi now publicly reimbursed in Ontario, Alberta, Saskatchewan and Quebec for the treatment of moderate to severe plaque psoriasis (Canada Newswire) – Feb 6, 2020 – “AbbVie…announced today that Ontario, Alberta, Saskatchewan and Quebec have listed SKYRIZI™ (risankizumab) on their respective provincial formularies for the treatment of moderate to severe plaque psoriasis.”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi US sales projection: $246M (consensus: $133M) in Q1 2020 (UBS) – Feb 3, 2020 – A subscription to Thomson ONE is required to gain full access to report 68727877; Page no: 1; REPORT TITLE: “US Pharmaceuticals “Drug launches – weekly tracker” Jacob”; AUTHOR: Jacob, Navin, et al; DATE: 01/27/2020

No Comments

Post a Comment

Comment
Name
Email
Website